You are here

Article Text

Article menu
Download PDFPDF
Letter
Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study
  1. E Collantes-Estévez1,
  2. M C Muñoz-Villanueva2,
  3. J D Cañete-Crespillo3,
  4. R Sanmartí-Sala3,
  5. J Gratacós-Masmitjá4,
  6. P Zarco-Montejo5,
  7. J C Torre-Alonso6,
  8. C González-Fernández7
  1. 1Rheumatology Service, Reina Sofia University Hospital of Córdoba, Spain
  2. 2Research Unit, Reina Sofia University Hospital of Córdoba, Spain
  3. 3Rheumatology Service, Clinic Hospital of Barcelona, Spain
  4. 4Rheumatology Service, Parc Taulí Hospital of Sabadell, Spain
  5. 5Rheumatology Service, Alcorcon Foundation Hospital of Madrid, Spain
  6. 6Rheumatology Service, Monte Naranco Hospital of Oviedo, Spain
  7. 7Rheumatology Service, Gregorio Marañón Hospital of Madrid, Spain
  1. Correspondence to:
    Professor E Collantes-Estévez. Servicio de Reumatología
    Hospital Universitario Reina Sofía. Avda Menéndez Pidal s/n, Córdoba-14011, Spain; eduardo.collantes.sspajuntadeandalucia.es

https://doi.org/10.1136/ard.2002.004879

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Some patients (20–30%) with spondyloarthropathies (SpA) have a persistent and disabling disease,1 for which a limited number of alternative therapeutic approaches exist.2 The successful results from randomised, double blind, placebo controlled trials in ankylosing spondylitis (AS) and SpA which have been published 3–5 suggest that treatment with infliximab is highly effective. However, in most of these studies, criteria for the selection of patients are based on active disease, but not on refractory disease (failure of response to previous drugs, including non-steroidal anti-inflammatory drugs (NSAIDs) and disease modifying antirheumatic drugs). Therefore, we aimed at assessing the effectiveness and safety of infliximab in patients with active and refractory SpA.

    PATIENTS AND METHODS

    The study was an open label, multicentre, 38 week prospective study in 40 patients with active and refractory SpA: 34 patients had AS, 3 had arthritis with related inflammatory bowel disease, and 3 undifferentiated SpA. Infliximab (5 mg/kg) was given at weeks 0, …

    View Full Text